Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. CEO Troy Wilson will join a panel discussion titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET. A live audio webcast will be accessible via the Investors section of Kura's website, with a replay available shortly after the event. Kura focuses on precision medicines for cancer, currently advancing drug candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancer types.
Kura Oncology, a clinical-stage biopharmaceutical company, will announce its second quarter 2021 financial results on August 5, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. ET. The company is focused on precision medicines for cancer treatment, with several drug candidates including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma. Kura's therapies aim to target specific cancer pathways and improve patient outcomes.
Kura Oncology, Inc. (Nasdaq: KURA) announced the appointment of Dr. Helen Collins to its board of directors. Dr. Collins, a veteran in medical oncology with over 25 years of experience, previously served as Chief Medical Officer at Five Prime Therapeutics. Her expertise will be instrumental as Kura advances its pipeline, including the KO-539 menin inhibitor in acute myeloid leukemia and the tipifarnib program for HRAS mutant head and neck squamous cell carcinoma. This strategic addition aims to enhance Kura's clinical development efforts and fulfill its mission of precision cancer therapies.
Kura Oncology, Inc. announced a clinical collaboration with Novartis to study the combination of tipifarnib and alpelisib for treating head and neck squamous cell carcinoma (HNSCC) driven by HRAS or PIK3CA pathways. This follows promising preclinical results indicating enhanced anti-tumor activity when both drugs target co-dependent pathways. The Phase 1/2 KURRENT trial is set to commence in the second half of 2021, aiming to potentially broaden tipifarnib's application among advanced HNSCC patients. Kura retains global rights to tipifarnib.
Kura Oncology announced the dosing of the first patient in the Phase 1b expansion of KOMET-001, targeting relapsed/refractory acute myeloid leukemia (AML) with its selective menin inhibitor, KO-539. The trial includes two cohorts: 200 mg and 600 mg doses, each enrolling at least 12 genetically enriched patients. KO-539 showed promising activity and a favorable safety profile in prior phases. The data obtained will aid in determining the recommended Phase 2 dose and potentially contribute to registration efforts. Kura aims to present future data at medical meetings.
Kura Oncology (Nasdaq: KURA) announced its participation in the JMP Securities Life Sciences Conference, with CEO Troy Wilson scheduled for a virtual presentation on June 17, 2021, at 3:00 p.m. ET. The live audio webcast will be accessible on Kura's website, with a replay available afterward. Kura focuses on precision medicines for cancer treatment, with promising candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancers, including acute myeloid leukemia and HRAS mutant head and neck cancer.
Kura Oncology (Nasdaq: KURA) announced the appointment of Carol Schafer to its board of directors, effective June 3, 2021. With over 25 years of experience in healthcare investment banking, including her recent role as Vice Chair of Equity Capital Markets at Wells Fargo Securities, Schafer is expected to contribute significantly to Kura’s strategic initiatives. She will succeed Robert Hoffman, who is stepping down from the board on August 3, 2021, after six years of service. Kura's pipeline includes promising cancer treatment candidates like KO-539 and Tipifarnib.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. CEO Troy Wilson will present in a fireside chat on May 20, 2021, at 10:20 a.m. PT. A live audio webcast will be available on the company's website, with a replay following the event. Kura's pipeline includes KO-539, a menin inhibitor in a Phase 1/2 trial, and Tipifarnib, a farnesyl transferase inhibitor with Breakthrough Therapy Designation, currently in a registration-directed study for head and neck cancer.
Kura Oncology reported its Q1 2021 financial results, highlighting the promising clinical activity and safety profile of its menin inhibitor KO-539. The KOMET-001 trial has been amended to include Phase 1b expansion cohorts for NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients. Kura maintains a solid financial position with $603.9 million in cash, expected to fund operations into 2024. The company also announced a publication of tipifarnib trial data in the Journal of Clinical Oncology and received Breakthrough Device Designation for an HRAS companion diagnostic.
Kura Oncology (KURA) will report its Q1 2021 financial results on May 6, 2021, after the U.S. markets close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed by dialing the provided numbers. Kura focuses on precision cancer treatments, with notable therapies in its pipeline, including KO-539 for acute myeloid leukemia and Tipifarnib for HRAS mutant head and neck cancer, which has received Breakthrough Therapy Designation.